Nonpharmacologic Treatment of Hypertension in Primary Health Care Norman M. KaplanDonald G. Vidt Clinical trials report Pages: 361 - 362
Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? Gozewÿn LavermanPiero RuggenentiGiuseppe Remuzzi OriginalPaper Pages: 364 - 367
Regression of left ventricular hypertrophy: Are there preferred drugs? Joseph A. DiamondRobert A. Phillips OriginalPaper Pages: 368 - 371
Isolated systolic hypertension and the risk of vascular disease Tim NawrotElly Den HondJan A. Staessen OriginalPaper Pages: 372 - 379
Hypertension and obstructive sleep apnea Bradley G. PhillipsVirend K. Somers OriginalPaper Pages: 380 - 385
Impact of the obesity epidemic on hypertension and renal disease John E. HallDaniel W. JonesJiankang Liu OriginalPaper Pages: 386 - 392
Cardiometabolic syndrome: Pathophysiology and treatment Jonathan P. CastroFadi A. El-AtatJames R. Sowers OriginalPaper Pages: 393 - 401
Chronic kidney disease: Blood pressure, treatment goals, and cardiovascular outcomes Matthew R. Weir Clinical Trials Report Pages: 405 - 407
RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease Jay LakkisWei X. LuMatthew R. Weir OriginalPaper Pages: 408 - 417
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Marc S. WeinbergNicholas KaperonisGeorge L. Bakris OriginalPaper Pages: 418 - 425
How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria? Julian SeguraHelle ChristiansenLuis M. Ruilope OriginalPaper Pages: 426 - 429
Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice? Douglas A. NigborJulia B. Lewis OriginalPaper Pages: 430 - 436